Drug intelligence / Profile preview

RLD2301 + RLD2007

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Administration: Oral

Overview

RLD2301 + RLD2007 is a combination of two investigational pharmaceutical agents developed by Hanmi Pharmaceutical, evaluated primarily for their drug-drug interaction and safety profile following oral administration in healthy adult volunteers. Both agents have been tested in a crossover design to assess pharmacokinetics, safety, and tolerability. Specific information regarding their molecular structure, precise pharmacological class, or mechanisms of action is not disclosed in the public domain.

Beyond the preview

Go deeper on RLD2301 + RLD2007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RLD2301 + RLD2007.

Explore the full profile